Anti-interferon alpha autoantibodies and their significance in COVID-19
During the last two years, treatment of patients with novel coronavirus infection COVID-19 remains an urgent health problem. Interferon proteins are known to play a significant role in antiviral immunity. Some pathological conditions are accompanied by production of neutralizing autologous immunoglo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Sankt-Peterburg : NIIÈM imeni Pastera
2022-05-01
|
| Series: | Инфекция и иммунитет |
| Subjects: | |
| Online Access: | https://iimmun.ru/iimm/article/viewFile/1789/1424 |
| _version_ | 1811212368016834560 |
|---|---|
| author | S. S. Petrikov N. V. Borovkova K. A. Popugaev Mayya V. Storozheva A. M. Kvasnikov M. A. Godkov |
| author_facet | S. S. Petrikov N. V. Borovkova K. A. Popugaev Mayya V. Storozheva A. M. Kvasnikov M. A. Godkov |
| author_sort | S. S. Petrikov |
| collection | DOAJ |
| description | During the last two years, treatment of patients with novel coronavirus infection COVID-19 remains an urgent health problem. Interferon proteins are known to play a significant role in antiviral immunity. Some pathological conditions are accompanied by production of neutralizing autologous immunoglobulins against own host interferons (auto-IFN-Abs). There is evidence that autoantibodies against interferons alpha and omega are detected in patients with life-threatening course of COVID-19 pneumonia. The aim of our study was to analyze prevalence of autoantibodies against interferon alpha in patients with COVID-19 coronavirus infection and assess their impact on clinical course of the disease. We examined 70 patients with severe COVID-19, who received inpatient treatment at the intensive care units. Serum autoantibodies against interferon alpha were determined on day 850 after disease onset by using solid-phase enzyme immunoassay (ELISA). Patients were divided into 2 groups: those with and without (group 2) autoantibodies against interferon alpha (group 1). Anti-COVID serum from 57 donors was used a control. Among patients, autoantibodies against interferon alpha were detected in 13 (18%) subjects, which level ranged from 26.8 to 1000 ng/ml. Among donors, auto-IFN-Abs were detected in 5 (8.8%) subjects at trace concentrations (from 1.65 to 12.0 ng/ml). Respiratory failure developed significantly more often in patients with auto-IFN-Abs. While analyzing laboratory parameters, it was noted that the concentration of C-reactive protein was significantly higher in the group of patients with auto-IFN-Abs. Mortality rate of patients with high auto-IFN-Abs levels was 60%. In conclusion, it was found that serum autoantibodies against IFN alpha in COVID-19 patients caused lung damage that significantly more often required hardware respiratory support, so comparable by duration with it for patients without auto-IFN-Abs. High concentrations of auto-IFN-Abs (more than 100 ng/ml) in patients with COVID-19 can be considered as a predictor of unfavorable disease outcome. |
| first_indexed | 2024-04-12T05:27:14Z |
| format | Article |
| id | doaj.art-a4a8d64ae2a34fc1989f74514d9ac1b0 |
| institution | Directory Open Access Journal |
| issn | 2220-7619 2313-7398 |
| language | Russian |
| last_indexed | 2024-04-12T05:27:14Z |
| publishDate | 2022-05-01 |
| publisher | Sankt-Peterburg : NIIÈM imeni Pastera |
| record_format | Article |
| series | Инфекция и иммунитет |
| spelling | doaj.art-a4a8d64ae2a34fc1989f74514d9ac1b02022-12-22T03:46:13ZrusSankt-Peterburg : NIIÈM imeni PasteraИнфекция и иммунитет2220-76192313-73982022-05-0112227928710.15789/2220-7619-AAA-17891136Anti-interferon alpha autoantibodies and their significance in COVID-19S. S. Petrikov0N. V. Borovkova1K. A. Popugaev2Mayya V. Storozheva3https://orcid.org/0000-0003-1927-2404A. M. Kvasnikov4M. A. Godkov5N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare DepartmentN.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare DepartmentN.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare DepartmentN.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare DepartmentN.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare DepartmentN.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare DepartmentDuring the last two years, treatment of patients with novel coronavirus infection COVID-19 remains an urgent health problem. Interferon proteins are known to play a significant role in antiviral immunity. Some pathological conditions are accompanied by production of neutralizing autologous immunoglobulins against own host interferons (auto-IFN-Abs). There is evidence that autoantibodies against interferons alpha and omega are detected in patients with life-threatening course of COVID-19 pneumonia. The aim of our study was to analyze prevalence of autoantibodies against interferon alpha in patients with COVID-19 coronavirus infection and assess their impact on clinical course of the disease. We examined 70 patients with severe COVID-19, who received inpatient treatment at the intensive care units. Serum autoantibodies against interferon alpha were determined on day 850 after disease onset by using solid-phase enzyme immunoassay (ELISA). Patients were divided into 2 groups: those with and without (group 2) autoantibodies against interferon alpha (group 1). Anti-COVID serum from 57 donors was used a control. Among patients, autoantibodies against interferon alpha were detected in 13 (18%) subjects, which level ranged from 26.8 to 1000 ng/ml. Among donors, auto-IFN-Abs were detected in 5 (8.8%) subjects at trace concentrations (from 1.65 to 12.0 ng/ml). Respiratory failure developed significantly more often in patients with auto-IFN-Abs. While analyzing laboratory parameters, it was noted that the concentration of C-reactive protein was significantly higher in the group of patients with auto-IFN-Abs. Mortality rate of patients with high auto-IFN-Abs levels was 60%. In conclusion, it was found that serum autoantibodies against IFN alpha in COVID-19 patients caused lung damage that significantly more often required hardware respiratory support, so comparable by duration with it for patients without auto-IFN-Abs. High concentrations of auto-IFN-Abs (more than 100 ng/ml) in patients with COVID-19 can be considered as a predictor of unfavorable disease outcome.https://iimmun.ru/iimm/article/viewFile/1789/1424sars-cov-2immunityinterferonsautoantibodiesimmunodeficiencycovid-19 |
| spellingShingle | S. S. Petrikov N. V. Borovkova K. A. Popugaev Mayya V. Storozheva A. M. Kvasnikov M. A. Godkov Anti-interferon alpha autoantibodies and their significance in COVID-19 Инфекция и иммунитет sars-cov-2 immunity interferons autoantibodies immunodeficiency covid-19 |
| title | Anti-interferon alpha autoantibodies and their significance in COVID-19 |
| title_full | Anti-interferon alpha autoantibodies and their significance in COVID-19 |
| title_fullStr | Anti-interferon alpha autoantibodies and their significance in COVID-19 |
| title_full_unstemmed | Anti-interferon alpha autoantibodies and their significance in COVID-19 |
| title_short | Anti-interferon alpha autoantibodies and their significance in COVID-19 |
| title_sort | anti interferon alpha autoantibodies and their significance in covid 19 |
| topic | sars-cov-2 immunity interferons autoantibodies immunodeficiency covid-19 |
| url | https://iimmun.ru/iimm/article/viewFile/1789/1424 |
| work_keys_str_mv | AT sspetrikov antiinterferonalphaautoantibodiesandtheirsignificanceincovid19 AT nvborovkova antiinterferonalphaautoantibodiesandtheirsignificanceincovid19 AT kapopugaev antiinterferonalphaautoantibodiesandtheirsignificanceincovid19 AT mayyavstorozheva antiinterferonalphaautoantibodiesandtheirsignificanceincovid19 AT amkvasnikov antiinterferonalphaautoantibodiesandtheirsignificanceincovid19 AT magodkov antiinterferonalphaautoantibodiesandtheirsignificanceincovid19 |